In bid to at­tract more R&D in­no­va­tion, Eu­rope looks to rewrite its phar­ma leg­is­la­tion

Phar­ma’s love af­fair with the US may see a slight turn of heart in the near fu­ture as Eu­ro­peans look to rewrite their phar­ma­ceu­ti­cal leg­is­la­tion be­fore the end of 2022, at least in part to make the re­gion more at­trac­tive and less bur­den­some for in­dus­try.

A few of the ma­jor rea­sons for re­work­ing the Eu­ro­pean phar­ma laws are to stim­u­late new break­throughs, ac­cord­ing to the Eu­ro­pean Com­mis­sion, par­tic­u­lar­ly in ar­eas of un­met need, in­crease the ac­ces­si­bil­i­ty of drugs across the con­ti­nent and to make the EU phar­ma sys­tem more at­trac­tive in an in­creas­ing­ly com­pet­i­tive glob­al en­vi­ron­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER